Rheumatoid Arthritis
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 6 days ago
#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE
Jiha Lee JihaRheum
1 week 6 days ago
TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205
Jiha Lee JihaRheum
1 week 6 days ago
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206
Aurelie Najm AurelieRheumo
1 week 6 days ago
RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA
-Primary endpoint DAS28-CRP change wk12
-2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01
-ACR20/50/70 + CDAI LDA all improved vs PBO
-hsCRP reduction across all dose arms
-69% CDAI LDA by wk14
-wk 28 extension shows https://t.co/AMfmSded0D
Aurelie Najm AurelieRheumo
1 week 6 days ago
A new MoA that does not meet it's primary endpoint in RA
SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib
ACR20 wk12 NOT significantly diff vs PBO
~48.5–61.8% across doses vs 52.3% PBO
Secondary BALI 200 mg QD:
ACR50: 36.9% vs 18.5% (nominal p=0.0179)
Mechanistic https://t.co/hmZ93JisiO
Antoni Chan MD (Prof) synovialjoints
1 week 6 days ago
Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026
Janet Pope Janetbirdope
1 week 6 days ago
#Rosnilimab works!! #PD1 agonist
In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis
Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA
#EULAR2026 @RheumNow
#OP0202 #EULARbest https://t.co/Jz92npXdgd
Aurelie Najm AurelieRheumo
1 week 6 days ago
SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA
Confirms what we already knew:
-Primary endpoint CDAI change wk26 not different
-Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034
-Better response in https://t.co/002n3sWtKs
Nelly ZIADE 🍀 Nellziade
1 week 6 days ago
🤰What happens to RA disease activity during pregnancy?
🔴 Most remain stable
🔴 70% with high disease activity at baseline improve
🔴 20% flare again post-partum
✨ACPA+ improve more
✨ Better outcomes after 2016 (after modern treatments)
OP0242 #EULAR2025 @rheumnow https://t.co/i3X566DcN6
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
Aurelie Najm AurelieRheumo
1 week 6 days ago
What if we let RA patients choose ttmt?
BACH RCT choice between Filgo / scTNFi vs. standard randomisation
55% JAKi vs 45% TNFi
Higher ttmt satisfaction 46 vs 33 p=0.012
Less ttmt switches 6 vs 15 p=0.026
Less AE reported
Better drug survival
Shared decision making is key! https://t.co/1YS0y6YUEH
Jiha Lee JihaRheum
1 week 6 days ago
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068
Dr. John Cush RheumNow
1 week 6 days ago
COMPARE Trial: CAR-T Cell Rx in 6 refractory active CCP+ RA pts (failed 4-7 prior b/tsDMARDs). After lymphodepletion w/ CTX + fludarabine, B cells depleted w/ neutropenia. Significant drops in CCP, RF, and DAS28, but at wk 12 only 50% ACR 20 response. Encouraging data but not https://t.co/txm32NkOKW
Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the biological, waits, returns. The pain persists.
